US FDA Exploring Options To Improve Study Of Drugs In Elderly
New incentives will most likely not be the immediate focus, but working group to explore ideas on enhancing understanding of drug effects in elderly populations will likely be formed by US FDA.
You may also be interested in...
FDA principal deputy commissioner Amy Abernethy and former commissioner Robert Califf point to success of orphan drug and pediatric exclusivity incentives in spurring drug development for neglected populations.
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.
Three former commissioners believe FDA has come through the Trump administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?